https://www.kaziatx.com/investors/news-and-events/press-releases/rss en-us https://s3.amazonaws.com/equisolve-dev4/kaziatherapeutics/files/theme/images/logo-sm.png /investors Equisolve Investor Relations Suite https://www.kaziatx.com/investors/news-and-events/press-releases/detail/218/kazia-therapeutics-limited-announces-pricing-of-up-to-120-million-public-offering Fri, 28 Aug 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/218/kazia-therapeutics-limited-announces-pricing-of-up-to-120-million-public-offering https://www.kaziatx.com/investors/news-and-events/press-releases/detail/217/kazia-therapeutics-limited-announces-proposed-public-offering Thu, 27 Aug 26 16:09:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/217/kazia-therapeutics-limited-announces-proposed-public-offering https://www.kaziatx.com/investors/news-and-events/press-releases/detail/216/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer Thu, 27 Aug 26 16:01:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/216/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/219/kazia-therapeutics-announces-the-filing-of-provisional-patent-for-novel-strategy-supported-by-preclinical-data-to-prevent-metastatic-recurrence-in-triple-negative-breast-cancer Tue, 28 Jul 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/219/kazia-therapeutics-announces-the-filing-of-provisional-patent-for-novel-strategy-supported-by-preclinical-data-to-prevent-metastatic-recurrence-in-triple-negative-breast-cancer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/215/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer Tue, 02 Jun 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/215/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/214/kazia-therapeutics-expands-ongoing-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer Tue, 26 May 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/214/kazia-therapeutics-expands-ongoing-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/213/kazia-therapeutics-strengthens-scientific-leadership-with-appointment-of-dr-sudha-rao-as-chief-scientific-officer-to-lead-next-generation-oncology-platform Wed, 15 Apr 26 08:00:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/213/kazia-therapeutics-strengthens-scientific-leadership-with-appointment-of-dr-sudha-rao-as-chief-scientific-officer-to-lead-next-generation-oncology-platform https://www.kaziatx.com/investors/news-and-events/press-releases/detail/212/kazia-therapeutics-expands-oncology-platform-with-first-in-class-setdb1-inhibitor-drug-development-platform Mon, 13 Apr 26 17:05:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/212/kazia-therapeutics-expands-oncology-platform-with-first-in-class-setdb1-inhibitor-drug-development-platform https://www.kaziatx.com/investors/news-and-events/press-releases/detail/85/kazia-therapeutics-announces-compelling-preclinical-and-translational-data-for-nuclear-pd-l1-degrader-ndl2 Fri, 30 Jan 26 08:00:00 -0500 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/85/kazia-therapeutics-announces-compelling-preclinical-and-translational-data-for-nuclear-pd-l1-degrader-ndl2 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/86/kazia-therapeutics-reports-encouraging-preliminary-clinical-responses-in-ongoing-phase-1b-study-of-paxalisib-in-late-stage-metastatic-triple-negative-breast-cancer Tue, 27 Jan 26 08:00:00 -0500 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/86/kazia-therapeutics-reports-encouraging-preliminary-clinical-responses-in-ongoing-phase-1b-study-of-paxalisib-in-late-stage-metastatic-triple-negative-breast-cancer